Immunovia publishes prospectus regarding preferential rights issue
Time table for the Rights Issue
26 September 2016 Last day of trading in the shares including subscription rights.
27 September 2016 First day of trading in the shares without the right to participate in the Rights Issue.
28 September 2016 Record date for participation in the Rights Issue. Registered shareholders included in the share register held by Euroclear Sweden AB will receive subscription rights carrying the right to participate in the Rights Issue.
3 October ‑ 17 October 2016 Subscription period.
3 October ‑ 13 October 2016 Trading in subscription rights.
3 October – 26 October 2016 Trading in paid subscribed shares (sw. BTA).
20 October 2016 The outcome of the Rights Issue is announced.
Beginning of November The Rights Issue is completed and registered.
Vator Securities AB is financial advisor to Immunovia and Baker & McKenzie Advokatbyrå KB is legal advisor to Vator Securities AB and Immunovia in connection with the Rights Issue.
For further information, contact:
Mats Grahn, CEO Immunovia AB
Phone: +46 (0)70-532 02 30
This information is information that Immunovia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.30 CET on 26 September 2016.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
This press release is not an offer or solicitation to acquire shares in Immunovia. A prospectus relating to the Rights Issue referred to in this press release will be filed with the Swedish Financial Supervisory Authority. After approval and registration of the prospectus by the Swedish Financial Supervisory Authority, the prospectus will be published and made available on i.e. Immunovia’s website.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Immunovia does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.